|
|
|
| Effect of synchronous iodine-125 seed strand implantation and transcatheter arterial chemoembolization in the treatment of primary hepatocellular carcinoma combined with portal vein main tumor thrombus |
| LIN Jiejun LU Lijie JIN Xiaojun BAO Luowen |
| Department of Gastroenterology, Wenzhou Central Hospital, Zhejiang Province, Wenzhou 325000, China |
|
|
|
Abstract Objective To evaluate the clinical effect of synchronous iodine-125(125I) seed strand implantation and transcatheter arterial chemoembolization (TACE) in the treatment of primary hepatocellular carcinoma combined with portal vein main tumor thrombus (PVTT). Methods From July 2013 to December 2016, 21 patients with hepatocellular carcinoma complicated by PVTT in Wenzhou Central Hospital were selected as the research subjects. Intravenous metal stents and 125I seed strips were implanted in sequential TACE therapy and all patients were followed up. Results A total of 21 portal vein stents were implanted and 10-18 particles per person. All patients were successfully implanted portal vein stents and 125I particle strips, with 100% success rate. No serious complications related to surgery occurred. A total of 38 times in 21 patients received TACE treatment, with an average of （1.8±0.9） times. There were no statistically significant differences in total bilirubin, prothrombin time, albumin and leukocyte counts between preoperative and postoperative of 30 d （P ＞ 0.05）. The mean survival time of patients was （389.1±79.9）d and the median survival time was 358.0 d. The cumulative survival rates of 90, 180 d and 360 d were 95.2%, 66.7% and 47.6%, respectively. The stent patency rates were 100.0%, 76.2% and 57.0%, respectively. Conclusion The clinical effect of synchronous 125I seed strand implantation and transcatheter arterial chemoembolization in the treatment of primary hepatocellular carcinoma combined with portal vein main tumor thrombus is better. It is worthy of clinical promotion and application．
|
|
|
|
|
|
[1] 黄乾荣，张玲.原发性肝癌治疗研究新进展[J].实用医学杂志，2016，32（14）：2275-2278.
[2] 谢正元，熊恺，郭武华.经颈静脉肝内门体分流术联合化疗在原发性肝癌伴门静脉癌栓治疗中的应用[J].中国介入影像与治疗学，2016，13（10）：600-604.
[3] 敖劲，曾令雯，刘衡，等.原发性肝癌DSA表现与TACE疗效的关系分析[J].中国普通外科杂志，2016，25（1）：51-56.
[4] 曹贵文，杜苗苗，崔新江，等.TACE联合125I放射性粒子植入序贯治疗近心旁原发性肝细胞肝癌效果观察[J].山东医药，2017，57（10）：55-57.
[5] 邹剑锋.放射性125I粒子置入联合TACE治疗对原发性肝癌患者血清标志物及肿瘤组织中凋亡分子的影响[J].海南医学院学报，2016，22（11）：1129-1132.
[6] Yang T，Lin C，Zhai J，et al. Surgical resection for advanced hepatocellular carcinoma according to Barcelona Clinic Liver Cancer（BCLC）staging [J]. J Cancer Res Clin Oncol，2012，138（7）：1121-1129.
[7] 雷振武.门静脉植入放射性支架联合肝动脉化疗栓塞治疗肝癌伴门静脉癌栓的疗效评估[J].中国现代医学杂志，2016，26（23）：111-114.
[8] 吴孟超.原发性肝癌伴门静脉癌栓的外科治疗[J].中华医学杂志，2004，84（1）：1-2.
[9] 孙世蒙，郭应兴，雷振武，等.TACE治疗原发性肝癌伴门静脉癌栓研究进展[J].介入放射学杂志，2017，26（7）：668-671.
[10] 王启明，梁军，杨海霞，等.肝动脉栓塞化疗联合与不联合放疗治疗肝细胞肝癌伴门静脉癌栓的效果比较[J].广东医学，2017，37（17）：2649-2652.
[11] 向斌，向华.TACE联合门静脉支架治疗伴门静脉癌栓原发性肝癌的效果分析[J].实用癌症杂志，2017，32（9）：1494-1497.
[12] 李文会，戴真煜，万豪光，等.125I粒子条联合门静脉支架及TACE序贯索拉非尼治疗肝癌合并门静脉主干癌栓[J].中华医学杂志，2016，96（23）：1838-1842.
[13] Zhang FJ，Li CX，Jiao DC，et al. CT guided 125iodine seed implantation for portal vein tumor thrombus in primary hepatocellular carcinoma [J].中华医学杂志：英文版，2008，121（23）：2410-2414.
[14] 毛晓楠，卢再鸣，郭启勇.门静脉支架联合125I粒子条植入治疗门脉癌栓12例[J].介入放射学杂志，2016，25（12）：1058-1064.
[15] 蒋丽，韩东明，胡鸿涛，等.125I粒子植入联合肝动脉化疗栓塞术预防原发性肝癌合并门静脉癌栓消化道出血[J].中华放射学杂志，2016，50（10）：784-788.
[16] 吴林霖，罗剑钧，颜志平，等.门静脉支架及经动脉药物治疗栓塞联合或未联合血管内植入碘-125粒子条治疗肝癌合并门静脉主干癌栓的比较[J].中华肝脏病杂志，2012，20（12）：915-919.
[17] 张磊，陆骊工，李勇，等.门静脉支架联合肝动脉化疗栓塞治疗肝癌伴门静脉癌栓的临床研究[J].介入放射学杂志，2011，20（12）：968-973.
[18] 王成刚，王小林，龚高全，等.金属内支架置入联合三维适形放射治疗肝癌合并门静脉癌栓[J].中华肝脏病杂志，2009，17（6）：417-421.
[19] 孙军辉，周坦洋，张岳林，等.门静脉支架联合125I粒子链植入序贯肝动脉灌注化学疗法栓塞术治疗肝癌伴门静脉癌栓[J].中华消化杂志，2014，34（1）：25-29.
[20] Luo JJ，Zhang ZH，Liu QX，et al. Endovascular brachytherapy combined with stent placement and TACE for treatment of HCC with main portal vein tumor thrombus [J]. Hepatol Int，2016，10（1）：185-195. |
|
|
|
